Introduction
============

Heart rate variability (HRV) has been suggested to measure as a noninvasive index for autonomic nervous control \[[@ref1],[@ref2]\]. Several studies have been reported the response of HRV to many effects on medications and stress in humans and animals \[[@ref3],[@ref4]\]. The HRV measurements have been used as a predictor of mortality in patients with cardiovascular conditions \[[@ref5]\]. The HRV contained time domain and frequency domain; time domain parameters are measured from the peak of N-N intervals or R-R peak of the electrocardiogram (ECG) which can be calculated as SDNN (standard deviation of the N-N intervals). Frequency domain or spectral analysis is measured by transforming ECG into a spectral signal. Previous study showed that the progression of cardiac conditions can be altered by cardiac autonomic activity leading to increase in heart rate (HR) and decrease in HRV \[[@ref6],[@ref7]\].

Morbidity, mortality, and complications due to anesthesia in geriatric and cardiac patients are considerably higher as compared to other medical disciplines \[[@ref8],[@ref9]\]. Many anesthetic protocols have been developed to improve the outcomes providing the safety for anesthesia in cardiac patients \[[@ref10],[@ref11]\]. Alfaxalone is a short-acting sedative with a fast onset of effects which is commonly used for inducing short-term anesthesia in patients; advantages of alfaxalone include muscle relaxation and rapid recovery \[[@ref12]\]. Previous studies reported that alfaxalone could provide minimal cardiovascular effects in dogs \[[@ref13]\]. Alfaxalone is considered safe and especially suitable for the patients suffering from heart disease, hypotension, and old age \[[@ref14]\]. Compared with zolazepam and tiletamine or propofol, alfaxalone shows a wider safety margin and greater therapeutic index over other anesthetic agents \[[@ref15],[@ref16]\]. However, according to various usages of anesthetic agents, so far no studies have been performed to analyze the cardiac autonomic activity using HRV to desire anesthetic agents that provided the minimal cardiovascular effects. The objective of this study was to evaluate the effects of various anesthetic agents on cardiac autonomic nervous activity using HRV analysis in dogs and to provide the information for clinical applications. We hypothesized that minimal effects on cardiovascular of anesthetic agents in a dog can be characterized by cardiac autonomic activity using HR and HRV analysis.

Animals
-------

Twelve client-owned dogs aged 3.9 **±** 1.0 years and weighing 15.0 **±** 2.3 kg were undergone the surgical procedure at the Kasetsart University Veterinary Teaching Hospital, Kamphaeng Saen. The owners of the dogs provided the necessary consents to approve the surgical procedure. The dogs were fasted 12 h prior to the surgery and were randomly assigned to four groups for four anesthetic protocols. The dogs of protocol 1 were pre-medicated and inducted with alfaxalone (at 3 mg/kg bwt). The dogs of protocol 2 anesthetized using zolazepam + tiletamine (at 5 mg/kg bwt). Similarly, diazepam (at 0.3 mg/kg bwt) + ketamine (at 5 mg/kg bwt) were used in protocol 3, and diazepam (0.3 mg/kg bwt) + propofol (at 5 mg/kg) were used in protocol 4. Then, all the dogs were maintained under anesthesia for approximately 1 h with a continuous infusion of 2% isoflurane with an oxygen flow rate of 1 l/min. All the parameters were recorded continuously for further analysis using a blinded assessment.

Clinical evaluations
--------------------

Routine laboratory evaluations (hematology and serum biochemistry analysis) were performed, as shown in [Table 1](#table1){ref-type="table"}. The ECG was recorded to evaluate the HR and HRV ([Figure 1](#figure1){ref-type="fig"}). Echocardiography was performed in parasternal long axis, short axis and apical four-chamber views in right and left parasternal positions. Echocardiographic images were captured and stored for offline analysis. Left ventricular wall structure and function were calculated by measuring the images from the two-dimensional plane ([Figure 2](#figure2){ref-type="fig"}).

HRV measurements
----------------

Noninvasive cardiac autonomic nervous control measurements were performed on 12 anesthetized client-owned dogs using a Holter ECG recording device (BTL medical technologies, Thailand). Three electrodes were placed on the shaved skin of the thorax with elastic tape to provide the 20 min ECGs recording for the baseline and 20 min after administering anesthetic drugs. The recorded ECGs from every 10 min sections were averaged and analyzed with analyzing program (BTL medical technologies, Thailand). The HRV was analyzed for the time domain and the frequency domain; time domain parameters were represented as the standard deviation of the R-R interval or SDNN and the frequency domain parameters were expressed as the activity in the high frequency (0.15--0.5 Hz) and low frequency (0.04--0.15 Hz).

Statistical analysis
--------------------

All data are showed as the mean ± standard error of the mean (mean ± SEM). Statistical analysis was performed using paired *t*-test and one-way ANOVA (GraphPad prism software version 5). A *p-*value of 0.05 or less was indicated for statistical significance.

Results and Discussion
======================

All the 12 dogs received successful surgery without any complications. There were no statistically differences between groups concerning mean age and body weight (*p* = 0.52 and *p* = 0.67, respectively). Results of blood profiles and cardiac function before the surgical procedure are summarized in [Tables 1](#table1){ref-type="table"} and [2](#table2){ref-type="table"}, respectively. Blood profiles and cardiac output in all groups remained within the normal range; there were no significant differences between the groups.

The HR was decreased after the drug administered in almost all groups except for the protocol 2. The dogs in the group of protocol 1 had the highest HR values (149 ± 0.8 beats/min), and the dogs in the group of protocol 4 had the lowest HR (140 ± 11.3 beats/min), as shown in [Table 3](#table3){ref-type="table"}. The mean blood pressure (MBP) was decreased but remained within the normal range in almost all protocols; however, the MBP due to protocol 4 was significantly decreased (*p* \< 0.05). The SDNN significantly decreased after anesthetic drug administration in the group of protocol 2 ([Table 4](#table4){ref-type="table"}) which indicated a reduction in parasympathetic tone related to the slight increase in the HR in this group. The highest values of low frequency (LF) power were found in the group of protocol 2 which indicated a vagal inhibition. The results from this study showed that zolazepam + tiletamine or Zoletil (protocol 2) produced an increase in HR and had an effect on the parasympathetic activity. The highest values of high frequency (HF) power were found in the group of protocol 1 indicated a high parasympathetic activity, and dogs in this group also had low values of the LF/HF ratio when compared with other protocols. This finding is similar to the previous report that the LF/HF ratio is usually low in a healthy person with sympatho-vagal balance \[[@ref17]\]. The results suggested that alfaxalone might preserve the cardiac autonomic activity balance. However, there were no marked HRV results on frequency domain variation were observed in any protocols. The results indicated that the ability of ECG Holter device to measure the frequency domain of the HRV in dogs was not substantially affected by the choice of anesthetic protocols. However, the anesthetized dog was significantly influenced by the HR and blood pressure ([Table 4](#table4){ref-type="table"}). An insufficient number of dogs in each group could affect the statistical analysis and this is the limitation of this study. Furthermore, only one set of ECG was recorded during 20 min, a recording at different periods of the surgical protocol may affect the results. HRV analysis in anesthetized dogs still requires further investigations to ensure validity for use in the future application.

###### Blood profiles in four group dogs.

                     Protocol 1    Protocol 2    Protocol 3    Protocol 4    Reference range
  ------------------ ------------- ------------- ------------- ------------- -----------------
  WBC (×10^3^/ul)    21.6 ± 9.2    18.1 ± 5.8    15.3 ± 2.2    37.8 ± 15.7   6--17
  RBC (×10^6^/ul)    6.1 ± 0.6     4.6 ± 0.03    7.2 ± 0.2     5.3 ± 0.2     5--9
  HGB (g/dl)         12.9 ± 1.1    10.4 ± 0.9    16.6 ± 0.3    11.2 ± 0.4    12--18
  HCT (%)            38.0 ± 3.0    31.4 ± 2.1    45.5 ± 0.2    33.5 ± 1.3    30--45
  PLT (×10^3^/ul)    223.7 ± 8.0   435.7 ± 6.5   207.3 ± 3.7   211.3 ± 9.8   200--900
  PROT (g%)          8.1 ± 0.7     7.8 ± 0.6     7.4 ± 0.2     7.6 ± 0.6     5.3--7.8
  Creatinine (mg%)   0.79 ± 0.01   0.86 ± 0.13   0.72 ± 1.0    1.06 ± 0.6    \<1.8
  ALT (IU/l)         62.5 ± 2.4    55.0 ± 1.8    66.0 ± 4.2    21.0 ± 0.1    \<89

Data represented as mean ± SEM

WBC = white blood cell, RBC = red blood cell, HGB = hemoglobin, HCT = hematocrit, PLT = platelet, PROT = total protein, ALT = Alanine aminotransferase

![A section of ECG signal obtained from Holter ECG recording.](JAVAR-5-485-g001){#figure1}

![Echocardiographic of transverse image of heart base (left) and M mode image of the left ventricle (right); AO= Aorta, LA = left atrium, and LV = left ventricle.](JAVAR-5-485-g002){#figure2}

###### Echocardiagraphic parameters in four groups of protocols.

  Parameters    Protocol 1    Protocol 2    Protocol 3    Protocol 4   Reference range
  ------------- ------------- ------------- ------------- ------------ -----------------
  IVSd (cm)     0.75 ± 0.04   1.1 ± 0.2     0.85 ± 0.05   0.87 ± 0.2   0.4--0.9
  LVIDd (cm)    1.4 ± 0.08    3.8 ± 1.3     1.5 ± 0.2     2.5 ± 1.5    2.0--2.5
  LVPWd (cm)    0.85 ± 0.1    1.0 ± 0.2     0.75 ± 0.04   0.8 ± 0.2    0.4--0.9
  IVSs (cm)     0.8 ± 0.04    1.2 ± 0.3     0.8 ± 0.1     0.8 ± 0.3    0.6--1.2
  LVIDs (cm)    1.1 ± 0.3     2.9 ± 0.9     1.0 ± 0.2     1.9 ± 1.2    1.2--2.1
  LVPWs (cm)    0.8 ± 0.1     1.0 ± 0.1     0.8 ± 0.03    0.9 ± 0.2    0.7--1.3
  EF (%)        71.5 ± 0.4    53.0 ± 6.2    78.5 ± 3.6    77.0 ± 5.6   49--81
  FS (%)        37.5 ± 0.5    25.0 ± 1.7    43.5 ± 3.7    37.0 ± 3.6   25--45
  LA/Ao Ratio   1.5 ± 0.04    1.62 ± 0.07   1.36 ± 0.08   1.5 ± 0.1    1.0--1.5
  EPSS (cm)     0.2 ± 0.08    0.6 ± 0.08    0.23 ± 0.08   0.4 ± 0.2    0.4--0.75

Data represented as mean ± SEM

IVSd = diastolic interventricular septum thickness, IVSs = systolic interventricular septum thickness, LVIDd = left ventricular end diastolic diameter, LVIDs = left ventricular end systolic diameter, LVPWd = left ventricular wall diastolic thickness, LVPWs = left ventricular wall systolic thickness. The left ventricular ejection fraction (EF); EPSS = E point of septum separation

###### The baseline of respiratory and cardiovascular parameters in four groups of protocols.

          Protocol 1     Protocol 2     Protocol 3     Protocol 4    *p* value
  ------- -------------- -------------- -------------- ------------- -----------
  RR      28.3 ± 6.0     15.0 ± 2.8     13.0 ± 1.5     19.3 ± 3.5    0.08
  HR      149 ± 0.8      145 ± 11.3     145.6 ± 17.5   140 ± 11.3    0.95
  SDNN    110 ± 31.6     108 ± 16.3     106.6 ± 48.6   83.0 ± 28.7   0.92
  LF/HF   0.72 ± 0.14    1.0 ± 0.2      0.89 ± 0.09    0.88 ± 0.2    0.71
  SBP     115.0 ± 20.2   116.0 ± 12.0   140.0 ± 20.0   145.0 ± 5.0   0.19
  DBP     66.6 ± 12.0    63.3 ± 5.7     103.3 ± 21.6   93.3 ± 12.6   0.17
  MBP     86.6 ± 16.6    86.6 ± 13.3    111.6 ± 23.5   115 ± 10.4    0.30

Data represented as mean ± SEM

RR = respiratory rate, HR = heart rate, SDNN = standard deviation of the N-N intervals, LF/HF = low frequency per high frequency ratio, SBP = systolic blood pressure, DBP = diastolic blood pressure, MBP = mean blood pressure

*p* \< 0.05 compared among group of protocols

###### HR, HRV, and MBP parameters in four groups of protocols.

                                                                        Protocol 1                                          Protocol 2                                           Protocol 3                                          Protocol 4
  ---------------- ---------------------------------------------------- --------------------------------------------------- ---------------------------------------------------- --------------------------------------------------- --------------------------------------------------
  HR               Baseline                                             149.0 ± 0.8[\*](#table4_fn1){ref-type="table-fn"}   145.0 ± 11.3                                         145.6 ± 17.5                                        140.0 ± 11.3
  After surgical   106.0 ± 12.1[\*](#table4_fn1){ref-type="table-fn"}   145.7 ± 20.7                                        117.6 ± 12.3                                         134.6 ± 22.6                                        
  SDNN             Baseline                                             110.0 ± 31.6                                        108.0 ± 16.3[\*](#table4_fn1){ref-type="table-fn"}   106.6 ± 48.6                                        83.0 ± 28.7
  After surgical   106.6 ± 69.6                                         46.5 ± 4.5[\*](#table4_fn1){ref-type="table-fn"}    110.3 ± 70.2                                         128.3 ± 58.6                                        
  LF               Baseline                                             0.17 ± 0.06                                         0.27 ± 0.2                                           0.15 ± 0.02                                         0.13 ± 0.02
  After surgical   0.16 ± 0.06                                          0.07 ± 0.04                                         0.45 ± 0.35                                          0.09 ± 0.03                                         
  HF               Baseline                                             0.61 ± 0.2                                          0.25 ± 0.1                                           0.16 ± 0.03                                         0.16 ± 0.01
  After surgical   0.4 ± 0.1                                            0.09 ± 0.02                                         0.42 ± 0.3                                           0.09 ± 0.04                                         
  LF/HF            Baseline                                             0.72 ± 0.14                                         1.0 ± 0.2                                            0.89 ± 0.09                                         0.88 ± 0.2
  After surgical   0.66 ± 0.1                                           0.95 ± 0.3                                          0.99 ± 0.24                                          1.15 ± 0.2                                          
  MBP              Baseline                                             86.6 ± 16.6                                         86.6 ± 13.3                                          111.6 ± 23.5                                        115 ± 10.4[\*](#table4_fn1){ref-type="table-fn"}
  After surgical   61.6 ± 7.2                                           76.6 ± 6.6                                          110.0 ± 10.0                                         78.3 ± 10.1[\*](#table4_fn1){ref-type="table-fn"}   

Data represented as mean ± SEM

HRV = heart rate variability, HR = heart rate, SDNN = standard deviation of the N-N intervals, LF = low frequency, HF = high frequency, LF/HF = low frequency per high frequency ratio, MBP = mean blood pressure

*p* \< 0.05 compared with baseline

Conclusions
===========

The findings of this study show that alfaxalone can be used as a pre-medication and intubation in dogs which produce less effect on cardiovascular function than other protocols. The results suggest alfaxalone can be used for cardiovascular stability in dogs during anesthesia.
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